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Abstract
Bevacizumab is approved as a maintenance treatment in first-line setting in advanced-stage III-IV ovarian cancers, because
GOG-0218 and ICON-7 phase III trials demonstrated progression-free survival benefits. However, only the subgroup of
patients with high-risk diseases (stage IV, and incompletely resected stage III) derived an overall survival (OS) gain in the
ICON-7 trial (4.8 months). The modeled CA-125 elimination rate constant K (KELIM) parameter, based on the longitudinal CA-
125 kinetics during the first 100 days of chemotherapy, is a potential indicator of the tumor primary chemo-sensitivity. In the
ICON-7 trial dataset, the OS of patients within the low- and high-risk disease groups was assessed according to treatment
arms and KELIM. Among the patients with high-risk diseases, those with favorable standardized KELIM of at least 1.0
(n¼214, 46.7%) had no survival benefit from bevacizumab, whereas those with unfavorable KELIM less than 1.0 (n¼244,
53.2%) derived the highest OS benefit (absolute difference ¼ 9.1 months, 2-sided log-rank P¼ .10; Cox hazard ratio ¼ 0.78, 95%
confidence interval ¼ 0.58 to 1.04, 2-sided P¼ .09).
In June 2018, the Food and Drug Administration approved beva-
cizumab in combination with carboplatin and paclitaxel, fol-
lowed by single-agent bevacizumab, for stage III or IV ovarian
carcinoma patients after initial surgical resection (1). This ap-
proval is based on the outcomes of 2 parallel phase III trials,
GOG-0218 (NCT00262847) and ICON-7 (NCT00483782), which
demonstrated benefits in progression-free survival with the ad-
dition of bevacizumab to standard first-line chemotherapy in
patients with advanced-stage III-IV ovarian cancers (2,3).
However, the best candidate population for adjuvant beva-
cizumab treatment prescription is still a subject of contro-
versy (4). Indeed, no benefit in overall survival (OS) with
bevacizumab was eventually found in the final survival anal-
ysis report of GOG-0218 (5). On the other hand, an additional
analysis of the ICON-7 trial reported by Oza et al. (6) demon-
strated that the specific predefined high-risk population,
which included all patients with stage IV and those with
unoperated or suboptimally debulked (>1 cm) stage III dis-
eases, derived a benefit in OS with bevacizumab addition:
median OS was 39.3 vs 34.5 months and absolute difference
4.8 months (P¼ .03).
The tumor chemo-sensitivity, as potentially assessed by the
modeled kinetics of CA-125 during chemotherapy, might be an-
other parameter to consider. The CA-125 elimination rate con-
stant K (KELIM) is an early modeled kinetic parameter, which
can be assimilated to a CA-125 clearance during systemic treat-
ment (7). It is calculated with a minimum of 3 CA-125 values
during the first 100 days of neoadjuvant or adjuvant chemother-
apy. The prognostic value of KELIM was initially reported in a
retrospective study of the CALYPSO phase III trial with recurrent
disease patients (7). The prognostic value of KELIM regarding
progression-free survival and OS was subsequently validated
(when considered as a continuous or categorical covariate) in
first-line setting on the data of more than 3030 patients enrolled
in 1 phase II and 3 phase III trials, including the ICON-7 trial
(8,9).
Here, the objective was to assess the potential complemen-
tary prognostic role of KELIM with respect to the Oza et al. (6)
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risk groups in the ICON-7 trial as a way of defining more accu-
rately the best candidate population for bevacizumab
prescription.
The model previously reported (8,9) was used to estimate
the modeled KELIM values of patients enrolled in the ICON-7
trial and then to characterize the optimized KELIM cutoff meant
to dichotomize KELIM using receiver-operating characteristics.
KELIM was standardized (std) by this cutoff (patient std KELIM
¼ patient KELIM:cutoff) and qualified as unfavorable if std
KELIM was less than 1.0 or favorable if std KELIM was at least
1.0 as a way of facilitating the clinical interpretation. Survival
analyses were performed using univariate log-rank test and
Cox model to assess the prognostic value of KELIM with respect
to the other prognostic factors within the low- and high-risk
patient groups defined by Oza et al., with a landmark time point
set up at 100 days. Indeed, the CA-125 kinetics was modeled
from day 0 to 100, and exclusion of the early progressions ob-
served during the first 100 days avoided the biases related to
the links between early progressions and CA-125 kinetics. All
statistical tests were 2-sided, and a P value less than .05 was
considered statistically significant.
Of 1528 patients enrolled in the ICON-7 trial, the data from
1386 patients (90.7%) could be assessed for survival. The respec-
tive median std KELIM were 1.14 days1 (interquartile range ¼ 6
0.58) and 0.96 days1 (interquartile range ¼ 6 0.57) within the
low-risk (n¼ 928) and high-risk (n ¼ 458) disease groups, re-
spectively. The median KELIM value (0.06 days1) was found to
be the best cutoff for dichotomizing KELIM. The independent
prognostic value of std KELIM, with respect to the other covari-
ates, was confirmed in multivariate analyses (Supplementary
Tables 1 and 2, available online). The lack of survival benefit
with the addition of bevacizumab in the low-risk group
(n¼ 928) was confirmed regardless of std KELIM value, with ex-
cellent median survivals longer than 50 months (Table 1; Figure
1). Among the high-risk disease group patients (n¼ 458), those
with a favorable std KELIM of at least 1.0 (n¼ 214, 46.7%) did not
experience OS benefit from bevacizumab addition (46.6 vs
48.2 months, log-rank P¼ .70, Cox hazard ratio ¼ 0.93, 95% con-
fidence interval [CI] ¼ 0.65 to 1.34). Only those with an unfavor-
able std KELIM less than 1.0 (n¼ 244, 53.2%) might have derived
a benefit from bevacizumab (median OS ¼ 29.7 months, 95% CI
¼ 24.0 to 35.2 months vs OS ¼ 20.6 months, 95% CI ¼ 17.6 to
23.2 months; absolute difference, 9.1 months; log-rank P¼ .10;
Cox hazard ratio ¼ 0.78, 95% CI ¼ 0.58 to 1.04, P¼ .09). The dif-
ference was statistically significant when considering noncen-
sored median survivals (Wilcoxon P¼ .004) (Supplementary
Table 3, available online). Of note, the survival gain potentially
provided by bevacizumab addition was not sufficient to reach
similar survivals with those of high-risk disease patients with
favorable KELIM (Table 1; Figure 1).
Five years after the Oza et al. (6) report, the present addi-
tional analysis of ICON-7 trial data suggests that the chemo-
sensitivity, as potentially assessed by the modeled CA-125 ki-
netic parameter KELIM, may be a complementary covariate to
consider for decision-making about bevacizumab prescription.
Approximately 47% of high-risk patients may not derive sur-
vival benefit from the costly addition of bevacizumab, whereas
the maximum survival gain (about 9 months) might be obtained
in the remaining 53% patients with poorly chemo-sensitive dis-
eases. Such a strategy would imply that all patients would be
treated with chemotherapy, and only those with high-risk dis-
ease and unfavorable std KELIM <1.0 calculated after 3-4 cycles
would receive adjuvant bevacizumab. These data should be
interpreted with caution because the limited number of T
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patients in subgroups reduced the power and the statistical sig-
nificance of the analyses. A validation in other datasets of the
hypothesis generated by the present outcomes is necessary.
The recent presentation of PAOLA-1 phase III trial outcomes
suggesting a potential benefit from olaparib addition to bevaci-
zumab in patients with incompletely resected stage III and
stage IV disease subgroups, contrarily to those of PRIMA and
VELIA trials, again raises the question of the best indication of
bevacizumab in patients with high-risk diseases (10–12). To be
useful in clinics, the KELIM model was implemented on http://
www.biomarker-kinetics.org, so any physician can calculate pa-
tient KELIM based on their observed CA-125 values (minimum 3
timepoints) during the first 100 days of adjuvant or neoadjuvant
chemotherapy.
Funding
This work was supported by Universite Claude Bernard Lyon
1 (France), the employer of OC.
Notes
Author contributions: TJP and ADC were involved in the analytic
concept and design and/or participated in the acquisition of the
data. OC, MT, JP, AL, CS, GF, and BY contributed to the statistical
analyses and participated in interpretation of the results. All
authors participated in critical revision of the manuscript for
important intellectual content. All authors read and approved
the final manuscript.
Role of the funder: The funder had no role in the design of
the study; the collection, analysis, and interpretation of the
data; the writing of the manuscript; and the decision to submit
the manuscript for publication.
Conflicts of interest: The authors declare no conflict of interest.
Acknowledgments: The authors thank all the patients and their
families, the investigators, study nurses, pharmacists, pathologists,
and all study teams, especially the Gynecologic Cancer InterGroup
and MRC Clinical Trial Unit at University College London.
References
1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-
approves-bevacizumab-combination-chemotherapy-ovarian-cancer.
2. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in
the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):
2473–2483.
3. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovar-
ian cancer. N Engl J Med. 2011;365(26):2484–2496.
4. Colombo N, Sessa C, Bois AD, et al. ESMO-ESGO consensus conference recom-
mendations on ovarian cancer: pathology and molecular biology, early and
advanced stages, borderline tumours and recurrent disease. Int J Gynecol
Cancer. 2019;29(4):728–760.
5. Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized
trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol.
2019;37(26):2317–2328. JCO1901009.
6. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without
bevacizumab for women with newly diagnosed ovarian cancer (ICON7): over-
all survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):
928–936.
Unfavorable KELIM; 
Chemotherapy alone
167 132 90 7 0
Favorable KELIM; 
Chemotherapy alone
287 258 220 25 0
Unfavorable KELIM; 
Chemotherapy + 
bevacizumab
178 138 93 8 0
Favorable KELIM; 
Chemotherapy + 
bevacizumab
296 272 217 21 0
127 67 30 2 0
96 80 52 6 0
117 74 36 2 0
118 102 62 4 0
Low-risk diseases
Favorable KELIM: chemotherapy
Favorable KELIM: chemotherapy + bevacizumab
Favorable KELIM: chemotherapy
Favorable KELIM: chemotherapy + bevacizumab
Unfavorable KELIM: chemotherapy + bevacizumab
Unfavorable KELIM: chemotherapy alone
Unfavorable KELIM: chemotherapy + bevacizumab
Unfavorable KELIM: chemotherapy alone:
High-risk diseases
Overall survival me (months) Overall survival me (months)
Su
rv
iv
al
pr
ob
ab
ili
ty
Numbers at risk
Figure 1. Kaplan-Meier curves of the overall survivals (OSs) of patients with low- or high-risk diseases according to Oza et al. (6) in the ICON-7 trial according to treat-
ment arms, and standardized CA-125 elimination rate constant K (KELIM) (favorable 1.0 vs unfavorable <1.0).
O. Colomban et al. | 3 of 4
7. You B, Colomban O, Heywood M, et al. The strong prognostic value of KELIM,
a model-based parameter from CA 125 kinetics in ovarian cancer: data from
CALYPSO trial (a GINECO-GCIG study). Gynecol Oncol. 2013;130(2):289–294.
8. Colomban O, Tod M, Leary A, et al. Early modeled longitudinal CA-125 kinet-
ics and survival of ovarian cancer patients: a GINECO AGO MRC CTU Study.
Clin Cancer Res. 2019;25(17):5342–5350.
9. You B, Robelin P, Tod M, et al. CA-125 ELIMination rate constant K (KELIM) Is
A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from
the Phase II CHIVA trial. Clin Cancer Res. 2020. DOI: 10.1158/1078-0432.ccr-
20-0054.
10. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy
and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):
2403–2415.
11. Gonzalez-Martin A, Pothuri B, Vergote I, et al. Niraparib in patients with
newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–2402.
12. Ray-Coquard I, Pautier P, Pignata S, et al. Phase III PAOLA-1/ENGOT-ov25 trial:
olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts)
with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-
based chemotherapy (PCh) plus bev. Ann Oncol. 2019;30(suppl_5):v894–v934.
10.1093/annonc/mdz394 2019.
4 of 4 | JNCI Cancer Spectrum, 2020, Vol. 4, No. 3
